BioSpace News Archive

Immunome, Inc. today announced the appointment of Andrew D. Badley, M.D., to the company’s COVID-19 Advisory Board.

Osmotica Pharmaceuticals plc today announced that J. Aaron Green will join the leadership team of RVL Pharmaceuticals, Inc.

Theratechnologies Inc. announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday, July 15, 2021.

Understanding Latin America’s need of self-sufficiency in order to face future pandemics, and with the preservation of life as a priority, we have created VaxThera: a SURA Company expert in the research, development and commercialization of vaccines in Colombia and the region.

Axcella Announces Initiation of EMMPOWER ℠ Phase 2 Clinical Trial of AXA1665

NeuroPace, Inc., a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced that it has received a National Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies®(BRAIN) Initiative that will provide up to $9.3 million over five years to evaluate the use of NeuroPace’s RNS® System to treat Lennox-Gastaut Syndrome (LGS)

Clover Biopharmaceuticals and Dynavax Technologies Corporation announced the execution of a commercial supply agreement of Dynavax’s CpG 1018™ advanced adjuvant, for use in Clover’s protein-based COVID-19 vaccine candidate, SCB-2019.

Aurinia Pharmaceuticals Inc. announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted toward disadvantaged populations at most risk of developing SLE and LN.

Genomic Testing Cooperative, a first-in-class diagnostic company based on a cooperative business model using the most recent advances in NGS technology, announced a collaboration with Elevation Oncology to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study.

Ocuphire Pharma today announced that the VEGA-1 Phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints.